Analysis of Rosuvastatin on a Thermo Scientific Syncronis C18 by HPLC/UV

Importance of the Topic

Rosuvastatin is a widely prescribed statin that selectively inhibits HMG-CoA reductase to lower cholesterol and reduce cardiovascular risk. Fast, precise analytical methods support pharmaceutical quality control and clinical monitoring.

Study Objectives and Overview

This application note demonstrates a rapid, isocratic reversed-phase HPLC/UV method using a Thermo Scientific Syncronis C18 column for rosuvastatin analysis, focusing on sub-two-minute elution and high reproducibility.

Methodology and Instrumentation

• Instrument: Thermo Scientific HPLC system equipped with photodiode array detector.
• Column: Syncronis C18, 5 μm, 50 × 4.6 mm.
• Mobile phase: 20 mM ammonium acetate (pH 3.01)/acetonitrile (1:1, v/v).
• Flow rate: 1.0 mL/min; column temperature: 30 °C; autosampler at ambient; UV detection at 242 nm; injection volume 5 μL.
• Data processing: Thermo Scientific ChromQuest 5.0 software.

Main Results and Discussion

The method achieved complete rosuvastatin elution in under two minutes (mean retention time 1.24 min). Repeatability over 10 injections produced %RSD values of 0.03% (retention time), 0.16% (peak area) and 0.40% (tailing factor), confirming exceptional precision and column performance.

Benefits and Practical Applications

• High sample throughput with sub-two-minute run times.
• Outstanding reproducibility for stringent quality control.
• Suitable for pharmaceutical formulations and adaptable to biological samples.

Future Trends and Opportunities

Emerging developments may include coupling to mass spectrometry for enhanced specificity, use of smaller particle or core-shell columns to further reduce analysis time and solvent use, and integration into automated workflows for real-time manufacturing quality assurance.

Conclusion

The presented isocratic HPLC/UV method on Syncronis C18 provides a fast, reliable, and reproducible approach for rosuvastatin analysis, addressing the needs of pharmaceutical laboratories and support of therapeutic monitoring.

Reference

1. Pelat M., Dessy C., Massion P., Desager J.-P., Feron O., Balligand J.-L. Journal of Circulation 2003, 107, 2480.
2. Trivedi R.K., Kallem R.R., Mullangi R., Srinivas N.R. Journal of Pharmaceutical and Biomedical Analysis 2005, 39(3-4), 661–669.